Ipamorelin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-15. Numbers and descriptions here follow the published literature rather than marketing material.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
==== Taiwan ==== In Taiwanese cuisine, they are called dōngfěn (Chinese: 冬粉; lit. 'winter flour'). They are a versatile ingredient used in soups, stir-fries, hot pots, and street food. A popular Taiwanese dish featuring glass noodles is bah-oân (肉圓), a translucent, doughy snack filled with meat and vegetables, often including glass noodles in the filling for added texture. Glass noodles are also a staple in Taiwanese-style lu wei (滷味), a braised food stall dish where various ingredients, including glass noodles, are simmered in a spiced soy-based broth and served hot or cold. In Hakka cuisine, a traditional preparation called kè jīa fěn sī (客家粉絲) involves stir-frying glass noodles with dried shrimp, mushrooms, pork, and preserved vegetables. Glass noodles are also often included in festive banquet dishes, such as steamed seafood casseroles and Buddha Jumps Over the Wall (佛跳牆), where they absorb rich flavours from broths and other ingredients. Taiwanese hot pots (火鍋) frequently include glass noodles as an essential add-in that soaks up the broth while maintaining a chewy texture, especially in spicy or medicinal broths popular in winter.
== Diagnosis == Kwashiorkor, or edematous malnutrition, like many other malnutrition diseases, is indirectly assessed using anthropometry. Kwashiorkor is a subtype of severe acute malnutrition (SAM) characterized by bilateral peripheral pitting edema. According to the World Health Organization, the SAM diagnosis parameters are a "mid-upper arm circumference (MUAC) of < 115 mm, weight-for-height/length Z-score (WHZ) of < -3Z and nutritional edema or any combination of these parameters." Additional clinical findings on physical exam include marked muscle atrophy, abdominal distension, dermatitis, and hepatomegaly. WHO criteria for clinical assessment of malnutrition are based on the degree of wasting (MUAC), stunting (weight-for-height Z-score), and the presence of edema (mild to severe). In addition to anthropometric measures, laboratory tests can be critical for diagnosing kwashiorkor. Low serum albumin levels (hypoalbuminemia) are a hallmark of protein deficiency, and elevated liver enzymes may indicate liver dysfunction. Electrolyte imbalances and blood tests may also be used to assess the degree of organ involvement and complications. Specifically in children, severe malnutrition, such as kwashiorkor, can lead to notable changes in brain function and behavior. Children with kwashiorkor tend to be irritable and may develop cerebral atrophy, whereas those with severe wasting frequently show apathy, reduced movement, and speech delays. These neurological and behavioral changes are key factors in the clinical assessment of malnutrition.
== History == The 5-HT2c receptor agonist Fenfluramine (market names Pondimin, Ponderax and Adifax) was discovered in 1972 as a result of research performed to identify anorectic compounds lacking the effects of psycho-stimulants and sympathomimetic agents (such as amphetamines). Prior to the discovery of fenfluramine, amphetamines were the primary form of anorectic drugs available, however the side effects made them difficult to use. Fenfluramine's anorectic effect is achieved through an increase in serotonin levels, imparting a sensation of fullness, which leads to a lower intake of food. Fenfluramine was sold as a racemic mixture of two enantiomers, dexfenfluramine and levofenfluramine. In 1994, sales of the combination drug Fen-phen (fenfluramine and phentermine) increased dramatically, as this combination produced substantial and apparent synergistic effect in promoting weight loss. Subsequently, reports of severe side effects associated with heart valve abnormalities and an increased risk of pulmonary hypertension resulted in a decision to remove products containing fenfluramine from the U.S. market, and then from other markets around the world. Dexfenfluramine inhibits serotonin reuptake, stimulating the release of serotonin. In 1996, dexfenfluramine became the first long-term treatment anti-obesity medication approved in the US; adverse effects observed during clinical trials included dry mouth, diarrhea and drowsiness. In the mid-1990s the US FDA approved dexfenfluramine as a weight loss drug.
Also in 1992, the Dow Corning Corporation, a silicone products and breast implant manufacturer, announced the discontinuation of five implant-grade silicones, but would continue producing 45 other, medical-grade, silicone materials—three years later, in 1995, the Dow Corning Corporation went bankrupt when it faced large class action lawsuits claiming a variety of illnesses.
This list of former players includes those who received international caps while playing for the team, made significant contributions to the team in terms of appearances or goals while playing for the team, or who made significant contributions to the sport either before they played for the team, or after they left. It is not complete or all inclusive, and additions and refinements will continue to be made over time.
Sources: en.wikipedia.org
Given its economic importance, indigo has been prepared by many methods. The Baeyer–Drewsen indigo synthesis dates back to 1882. It involves an aldol condensation of o-nitrobenzaldehyde with acetone, followed by cyclization and oxidative dimerization to indigo. This route was highly useful for obtaining indigo and many of its derivatives on the laboratory scale, but proved impractical for industrial-scale synthesis. Johannes Pfleger and Karl Heumann eventually came up with industrial mass production synthesis from aniline by using mercury as a catalyst. The method was discovered by an accident by Karl Heumann in Zurich which involved a broken thermometer. The first commercially practical route of producing indigo is credited to Pfleger in 1901. In this process, N-phenylglycine is treated with a molten mixture of sodium hydroxide, potassium hydroxide, and sodamide. This highly sensitive melt produces indoxyl, which is subsequently oxidized in air to form indigo. Variations of this method are still in use today. An alternative and also viable route to indigo is credited to Heumann in 1897. It involves heating N-(2-carboxyphenyl)glycine to 200 °C (392 °F) in an inert atmosphere with sodium hydroxide. The process is easier than the Pfleger method, but the precursors are more expensive. Indoxyl-2-carboxylic acid is generated. This material readily decarboxylates to give indoxyl, which oxidizes in air to form indigo. The preparation of indigo dye is practised in college laboratory classes according to the original Baeyer–Drewsen route.
Original (black can with green logo) Zero Sugar (originally had dark blue logo; changed to resemble Original can with the top recolored green with a black pull tab) Lo-Carb (black can with dark blue logo) Assault (cola flavor, stylized camouflage can with red logo) Reserve White Pineapple (pineapple flavor, black can with yellow logo and yellow band around flavor title) Reserve Orange Dreamsicle (orange flavor, black can with orange logo) Reserve Watermelon (watermelon flavor, black can with red logo) Ripper (tropical fruits flavor, yellow can) Cuba-Libre (cola and lime flavor version of the cuba libre cocktail.) Dub Mad Dog (grape flavor, discontinued) Maxx (original flavor with added nitrous oxide, comes in a variety of flavors) Nitro Super Dry (citrus flavor; utilizes nitrous oxide rather than carbon dioxide, giving the beverage a light & dry texture (mouthfeel) similar to that of fine champagne, black can with black logo shrouded in lime green) Mule (ginger beer flavor, zero sugar, matte finish black can with bronze logo and text with 'Non-alcoholic', inspired to the Moscow Mule cocktail) VR46 The Doctor (orange flavor, yellow can with Valentino Rossi's The Doctor branding) LH44 Lewis Hamilton (red can with yellow and black patterns with black logo) Full Throttle (previously named Lewis Hamilton too, blue can with white text and yellow logo) Java (Coffee mixed with Monster Energy available in a variety of flavors including salted caramel, loca moca, Irish cream, and mean bean.) Pacific Punch (cherry punch flavor) Pipeline Punch (passion fruit, orange and guava flavor, pink can) Mixxd (Punch line. Cherry flavor, surface-textured purple can.) Monarch (juiced line, pastel pink can with yellow logo and Monarch butterfly artwork) Mango Loco (juiced line, blue can with orange logo and artwork themed to the Mexican Day of the Dead) Khaotic (juiced line, yellow can with light blue logo and graffiti butterfly artwork) Aussie Lemonade style (Juiced line, blue can with yellow logo and artwork featuring a variety of sea creatures. Citrus flavored. Introduced in 2022) Bad Apple (juiced line, red apple flavor, punky/alt version of Eve holding an apple) Rio Punch™ (juice line, sweet papaya, vanilla ice cream, hint of blackcurrant, green can with yellow diamond themed to the Brazilian flag.) Viking Berry™ (juice line, mixed nordic berries, blackberry, black currant, hint of lingonberry, sweet and tart profile, red and light blue can with norse themed art.) Voodoo Grape™ (juice line, Concord, Niagara, and red grape profile, yellow and purple can with Louisiana voodoo-themed artwork) Zero Ultra (citrus flavor, zero sugar, textured white can with silver logo) Commonly known as "White Monster" Lando Norris Zero Sugar (melon yuzu flavour, black can with neon yellow pattern) Ultra Blue (blue raspberry flavor with a light citrus and berry flavor profile, zero sugar, textured light blue can with silver logo) Ultra Fantasy Ruby Red (grapefruit flavor, zero sugar, textured magenta can with silver logo) Ultra Fiesta (mango flavor, zero sugar, textured blue can with silver logo) Ultra Watermelon (watermelon flavor, zero sugar, textured bright red can with silver logo) Ultra Paradise (apple and kiwi flavor, zero sugar, textured lime green can with silver logo) Ultra Rosá (pink lemonade flavor, zero sugar, textured hot pink can with silver logo) Ultra Gold (pineapple flavor, zero sugar, textured gold can with silver logo) Ultra Vice Guava (guava flavor, zero sugar, textured teal can with pink-white logo) Ultra Red (mixed berry flavor, zero sugar, red can) Ultra Black (cherry flavor, zero sugar, textured black can with silver logo) Ultra Peachy Keen (Peach flavor, zero sugar, textured peach can with silver logo. Made in limited edition form.) Ultra Sunrise (Orange flavor, zero sugar, orange can with silver logo) Ultra Strawberry Dreams (strawberry flavor, zero sugar, pink can) Ultra Passion (passionfruit flavour) Ultra Red, White, and Blue (rocket pop flavour) Ultra Violet, a.k.a. The Purple Monster (grape flavor, zero sugar, violet can)
No figures are available on how many orphaned children also had been injured, but Gaza was reported to have the highest proportion of child amputations of any contemporary conflict. Medical workers said that while they can provide treatment for children's physical injuries, there is little lasting stability or support afterward. With most social institutions in collapse, only small community networks and aid groups remain to care for orphaned children or try to locate surviving relatives, efforts that are minimal compared with the overwhelming need. War Child is among the few humanitarian organisations contacted by emergency clinics about WCNSF cases. Its social workers search displacement camps for unaccompanied children and work to place them with adults willing to provide care. However, locating families willing to take in children is exceptionally difficult amid severe food shortages, and transporting a wounded child is very expensive. Amid worsening scarcity, many children, particularly boys, are banding together to survive, searching through rubbish for food or items to sell, and gathering in groups at food distribution sites, a perilous strategy born of extreme need.
== Signs and symptoms == The consumption of large quantities of Lathyrus seeds containing high concentrations of the neurotoxic glutamate analogue β-oxalyl-L-α,β-diaminopropionic acid (ODAP, also known as β-N-oxalyl-amino-L-alanine, or BOAA) causes paralysis, characterized by lack of strength in or inability to move the lower limbs, and may involve pyramidal tracts, producing signs of upper motor neuron damage. The toxin may also cause aortic aneurysm. A unique symptom of lathyrism is the atrophy of gluteal (buttocks) muscles. ODAP is a poison of the mitochondria, leading to excess cell death, especially in motor neurons. Children can additionally develop bone deformity and reduced brain development.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.